May 9, 2022
By
"I SERIOUSLY expect that a series of new highly virulent and highly
infectious SARS-CoV-2 (SC-2) variants will now rapidly and independently emerge
in highly vaccinated countries all over the world and that they will soon
spread at high pace. I expect the current pattern of repetitive infections and
relatively mild disease in vaccinees to soon aggravate and be replaced by
severe disease and death. Unfortunately, there is no way vaccinees can rely on
assistance from their innate immune system to protect against coronaviruses as
their relevant innate IgM antibodies are increasingly being outcompeted by
infection-enhancing vaccinal Abs, which are continuously recalled due to the
circulation of highly infectious Omicron variants. In contrast, Omicron’s high
infectiousness would enable the non-vaccinated to train their innate immune
defense against SC-2 while the infectious and pathogenic capacity of the new
SC-2 variants would be debilitated in the non-vaccinated for lack of
infection-enhancing Abs in their blood. Unless..."
READ ALL THE PAPER => https://uploads-ssl.webflow.com/616004c52e87ed08692f5692/627933433cc6dc1c869df8ad_GVB%27s%20analysis%20of%20C-19%20evolutionary%20dynamics%20update%20May%202022.pdf
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda
Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior
Program Officer; he then worked with the Global Alliance for Vaccines and
Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he
tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora
with other partners, including WHO, to review progress on the fight against
Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the
safety of the Ebola vaccine that was used in ring vaccination trials conducted
by WHO in Guinea. His critical scientific analysis and report on the data
published by WHO in the Lancet in 2015 was sent to all international health and
regulatory authorities involved in the Ebola vaccination program. After working
for GAVI, Geert joined the German Center for Infection Research in Cologne as
Head of the Vaccine Development Office. He is at present primarily serving as a
Biotech / Vaccine consultant while also conducting his own research on Natural
Killer cell-based vaccines.
Email: info@voiceforscienceandsolidarity.org
